Forte Biosciences (FBRX) Current Leases (2019 - 2020)
Forte Biosciences (FBRX) posted quarterly Current Leases of $435000.0 for Q1 2020, down 45.35% year-over-year from $796000.0 in Q2 2019, and up 4.57% quarter-over-quarter from $416000.0 in Q4 2019.
Powered by 
Analysis
Forte Biosciences (FBRX) Current Leases (2019 - 2020) Analysis & Trends
Forte Biosciences (FBRX) has reported Current Leases for 2 consecutive years, with $435000.0 the latest figure, recorded in Q1 2020.
- In Q1 2020, Current Leases fell 45.35% year-over-year to $435000.0; the TTM figure through Mar 2020 stood at $435000.0 (down 45.35% YoY), while the FY2019 annual figure was $416000.0, changed N/A from the prior year.
- Current Leases advanced to $435000.0 in Q1 2020 per FBRX's latest filing, from $416000.0 in the prior quarter.
- Across five years, Current Leases topped out at $876000.0 in Q3 2019 and bottomed at $416000.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | 435,000.00 |
| Dec 31, 2019 | 416,000.00 |
| Sep 30, 2019 | 876,000.00 |
| Jun 30, 2019 | 836,000.00 |
| Mar 31, 2019 | 796,000.00 |